G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance
August 2, 2023 6:34 AM EDTG1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of $0.14, $0.36 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $42.4 million versus the consensus estimate of $28.95 million.
G1 today reiterated its full year 2023 net revenue guidance. The Company expects to generate... More
